We transform the most promising oncology innovations into highly competitive opportunities that benefit patients, researchers, investors, and Ontario's economy. Cancer Breakthroughs. Realized.

About

We know the business of science.

Funds

We bridge the funding gap.

Investment Opportunities

We are the gateway to Ontario's oncology assets.

FACIT Features: Notch Therapeutics Closes $85M USD Series A for Renewable Stem Cell-Derived Cancer Immunotherapies

Notch is a Canadian biotech incubated by Ontario-based Centre for Commercialization of Regenerative Medicine (CCRM)

The financing is one of the largest Series A financing round in Canadian biotech history, notably at a time of heightened interest by Ontario in commercializing homegrown intellectual property. 


FACIT crowns 2021 winner of Falcons’ Fortunes pitch competition; announces follow-on investment in 2020 winner, Bridge7 Oncology

Showcasing Ontario’s emerging biotech entrepreneurs and driving value from intellectual property

FACIT's Prospects Oncology Fund and its annual pitch competition help to advance Ontario oncology innovations. 


FACIT welcomes life sciences executive Ken Newport to its Board; Director Shana Kelley appointed to the Order of Ontario

Blend of scientific, industry, investment and entrepreneurial expertise complements FACIT’s leading role in growing Ontario’s life sciences commercialization

Mr. Newport is a passionate executive and advocate of Ontario’s life science sector, having decades of leadership experience in both public and private ventures.


FACIT fuels promising made-in-Ontario breast cancer therapeutic and medtech innovations through Prospects Oncology Fund

Ontario First capital supports early stage commercialization of cancer intellectual property

The newest recipients of Ontario First seed capital include Dr. Rebecca Laposa of the University of Toronto, as well as London-based start-up Multi-Magnetics Inc.


FACIT Features: Triphase Accelerator reports positive interim results of lead compound in Phase 1 Clinical Trial for Lymphoma

The encouraging study results includes six complete remissions in previously-treated lymphoma patients.

FACIT congratulates Triphase Accelerator on interim results from its ongoing Phase 1 multi-center, open-label monotherapy study of TRPH-222.


FACIT Features: DNAstack to lead and develop COVID Cloud for Canada’s Digital Technology Supercluster

The COVID Cloud will enable accelerated and more insightful interpretation of COVID-19, leading to increased preparedness for future outbreaks, and identification of potential treatments.

FACIT is pleased to accept the invitation to join the national consortium as Lead Commercialization Advisor. 


Latest Tweet / Follow

Contact Us